Minretumomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | TAG-72 |
| Identifiers | |
| CAS Number | 195189-17-4  |
| ATC code | V09IX03 (WHO) (125I radiolabelled) |
| Synonyms | CC49 |
 (what is this?) (verify) |
|
Minretumomab (CC49) is a mouse monoclonal antibody[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.[2][3] Apparently, it never got past Phase I clinical trials for this purpose.[4]
Derivatives
A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric[5] and humanized minretumomab,[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.[7]
Radiopharmaceuticals
Iodine (125I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.[8]
Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (131I) and lutetium (177Lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.[5]
References
- ↑ WHO Drug Information.
- ↑ TAG-72 antigen entry in the public domain NCI Dictionary of Cancer Terms.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ CC49 on ClinicalTrials.gov.
- ↑ 5.0 5.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
